The results of this prospective single-center cohort, which included 907 consecutive patients with nonvalvular AF on vitamin K antagonists, showed that the ABC pathway significantly reduced the risk of cardiovascular events in AF patients [64]. This evidence concerns the gene ABCB6 and atrial fibrillation.